I spoke with the CFO last week; my vibe is they are nowhere near a partner. Got the old, "they want to see more mature data and/or see how the FDA meetings go"
If they can do a small single arm pivotal study for 011, I would prefer they go it without a partner because all a partner would bring to the table is money, and would most likely delay the trial for 6 months or more. If they need to do a large scale 800 person trial, they will NEED to partner because these guys would screw it up on their own. Either way, theyre gonna be raising more capital in 2013 I can guarantee you that.
BTW, did CEO say if they have dose any patients in 1135 yet?
CLDX
